Medlab Clinical Limited (MDC) 2020年年度报告「ASX」.pdf

1、Who we areAn Australian Biotechnology company focusing on chronic illnessesPOINT OF DIFFERENCERESEARCHEVIDENCEPATENTSAPPROVALGLOBAL3 CORE REVENUE STREAMS1Early market access for newdrugsPartnering23NutraceuticalRange3 IN-MARKET SEGMENTSDRUG DEVELOPMENT:a non-opioid analgesic for CIBP(cancer induced

2、bone pain)PLATFORM DEVELOPMENT:a unique submicron delivery platform for improving drug solubilityNUTRACEUTICALS(AU):Via AU Pharmacies,with several under clinical investigationPARTNERING(GLOBAL):Partnering agreementsfor 3rd party use ininternational territoriesCONTENTSChairmans Letter4CEO Report5Dire

3、ctors Report9Auditors Independence Decl aration20Financial Statements21Directors Decl aration50Independent Auditors Report51Sharehol der Information54Corporate Directory56CHAIRMANS LETTERDear Sharehol ders,It is my pl easure to present Medl ab Cl inical s 2020 Annual Report.This has been a pivotal y

4、ear for Medl ab Cl inical.Our focus has shifted towards drug devel opment l eadingwith our cannabinoid portfol io.We have successful l y compl eted a Phase I/II cl inical trial of our l ead candidateNanaBis which is targeting the treatment of bone pain in breast and prostate cancer patients.This is

5、anarea of great unmet need and where there is currentl y a high rel iance on opioids.Our strategy is to expand our market opportunity by gaining US regul atory approval for our cl inical l y val idated,medical cannabis-based product(NanaBis).Furthermore,the superior performance we can achieve via ou

6、r drug del ivery pl atform,NanoCel l ewil l be a key differentiator and we are on the j ourney to buil d a body of cl inical and real worl d evidence to support this.The mil estones achieved over the past 12 months and the capital raised puts us on track to commence the process offil ing an investig